How To Extrapolate For Biosimilars: New Guidance From International Regulators’ Forum
Executive Summary
The international regulators’ forum, the IPRF, has produced guidance on the issues associated with extrapolation that national regulatory bodies should take into consideration when evaluating biosimilar medicines submitted for approval.
You may also be interested in...
Regulators Work On Global Biosimilar Extrapolation Rules, MAb Assessments
As part of its regulatory convergence effort, the International Pharmaceutical Regulators Forum is working on two projects intended to help align global requirements regarding the extrapolation of indications for biosimilar medicines and the assessment of biosimilar monoclonal antibodies (MAbs).
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.